title: Pharmaceutical Approval Update.
abstract: Obeticholic acid (Ocaliva) for primary biliary cholangitis; sofosbuvir 400 mg/velpatasvir 100 mg (Epclusa) for chronic hepatitis C virus infection; and daclizumab (Zinbryta) for relapsing multiple sclerosis.
authors.forename: Michele B
authors.initials: MB
authors.lastname: Kaufman